There is currently a national shortage of carbamazepine CR (controlled release) tablets due to manufacturing disruptions and demand increases. Products impacted include Sandoz-Carbamazepine CR (200mg and 400mg) and Tegretol CR (200mg and 400mg). The shortage is expected to continue throughout the summer. On May 10, 2024, a Tier 3 shortage was declared for carbamazepine CR tablets. There are currently no anticipated shortages of carbamazepine IR (immediate release) tablets.
Information and resources
- Carbamazepine Controlled-Release (CR) Shortage (CPhA)
- Joint letter to health-care providers (Canadian League Against Epilepsy/CPhA)
